3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Recurrence
2
Meningioma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Neoplasm Metastasis
1
Muscle Invasive Bladder Cancer
1
Lung Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Endometrial Neoplasms
1
Disease
1
DLBCL
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma
1
Advanced Solid Malignancies
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Interventions
Nivolumab
20
Ipilimumab
10
Paclitaxel
7
linrodostat
6
Standard of Care
6
Sirolimus
5
Gemcitabine
5
Bevacizumab
5
temsirolimus
4
relatlimab
4
Pemetrexed
4
Docetaxel
4
Carboplatin
4
ARRY-334543
4
Vorinostat
3
Erlotinib Hydrochloride
3
Dasatinib
3
Cetuximab
3
regorafenib
2
olaparib
2
apatinib
2
anlotinib
2
abemaciclib
2
Trastuzumab
2
Surveys and Questionnaires
2
Sunitinib
2
Sorafenib
2
Olanzapine
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Cancer
×
vistusertib
×
Clear all
NCT02193633
2024-09-26
TAX-TORC
Royal Marsden NHS Foundation Trust
Phase 1
Completed
90 enrolled